Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study - Summary - MDSpire

Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study

  • By

  • Ryan T Demmer

  • Chaoqi Wu

  • John S Kim

  • Yifei Sun

  • Pallavi Balte

  • Mary Cushman

  • Rebekah Boyle

  • Russell P Tracy

  • Linda M Styer

  • Taison D Bell

  • Michaela R Anderson

  • Norrina B Allen

  • Pamela J Schreiner

  • Russell Bowler

  • David A Schwartz

  • Joyce S Lee

  • Vanessa Xanthakis

  • Jean M Rock

  • Rachel Bievenue

  • Amber Pirzada

  • Margaret Doyle

  • Elizabeth A Regan

  • Barry J Make

  • Alka M Kanaya

  • Namratha R Kandula

  • Sally E Wenzel

  • Josef Coresh

  • Carmen R Isasi

  • Laura M Raffield

  • Mitchell S V Elkind

  • Virginia J Howard

  • Victor E Ortega

  • Prescott Woodruff

  • Shelley A Cole

  • Joel M Henderson

  • Nicholas J Mantis

  • Elizabeth C Oelsner

  • March 20, 2025

  • 0 min

Share

Objective:

To investigate correlates of anti-nucleocapsid antibody responses following SARS-CoV-2 infection in a US population-based meta-cohort of adults, contributing to understanding immune responses and informing public health strategies.

Key Findings:
  • 69% of participants were reactive to nucleocapsid antibodies at 4 months post-infection, declining to 44% at ≥12 months, indicating waning immunity.
  • Higher anti-nucleocapsid antibody responses were associated with older age, Hispanic or American Indian Alaskan Native race/ethnicity, lower income, lower education, former smoking, and higher anti-spike antibody levels, suggesting socio-economic and demographic influences.
  • Asian race and vaccination were linked to lower nucleocapsid reactivity, highlighting the need for tailored public health interventions.
Interpretation:

The study highlights the dynamics of anti-nucleocapsid antibody responses and identifies sociodemographic and health-related factors influencing these responses, which may inform clinical practice and serosurveillance.

Limitations:
  • Potential misclassification of infection history due to reliance on self-report and hospital records, which may skew results.
  • Limited representation of certain demographics and health conditions in the study population, potentially affecting generalizability.
Conclusion:

Understanding the correlates of anti-nucleocapsid antibody responses can aid in identifying high-risk individuals for adverse COVID-19 outcomes and improve serological assessments, ultimately informing public health strategies.

Original Source(s)

Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study

  • by Ryan T Demmer, Chaoqi Wu, John S Kim, Yifei Sun, Pallavi Balte, Mary Cushman, Rebekah Boyle, Russell P Tracy, Linda M Styer, Taison D Bell, Michaela R Anderson, Norrina B Allen, Pamela J Schreiner, Russell Bowler, David A Schwartz, Joyce S Lee, Vanessa Xanthakis, Jean M Rock, Rachel Bievenue, Amber Pirzada, Margaret Doyle, Elizabeth A Regan, Barry J Make, Alka M Kanaya, Namratha R Kandula, Sally E Wenzel, Josef Coresh, Carmen R Isasi, Laura M Raffield, Mitchell S V Elkind, Virginia J Howard, Victor E Ortega, Prescott Woodruff, Shelley A Cole, Joel M Henderson, Nicholas J Mantis, Elizabeth C Oelsner

  • March 20, 2025

Related Content

The CRISPR-powered Diagnostic SLEUTH

Novel DNA-guided system may support future RNA diagnostics and mutation detection

  • May 22, 2026

  • 2 min
Serum cytokine profiling reveals CXCL10 (IP-10) as a major predictor of severe COVID-19 outcomes in hospitalized patients during the first pandemic wave in Italy

Immune remodeling and metabolic reprogramming in chronic fatigue: insights into GPCR signaling and epigenetic regulation